BACKGROUND: Ovarian cancer (OC) is mostly diagnosed in advanced stages with high incidence-to-mortality rate. Nevertheless, some patients achieve long-term disease-free survival. However, the prognostic markers have not been well established. OBJECTIVE: The primary objective of this study was to analyse the association of the suggested prognostic marker rs2185379 in PRDM1 with long-term survival in a large independent cohort of advanced OC patients. METHODS: We genotyped 545 well-characterized advanced OC patients. All patients were tested for OC predisposition. The effect of PRDM1 rs2185379 and other monitored clinicopathological and genetic variables on survival were analysed. RESULTS: The univariate analysis revealed no significant effect of PRDM1 rs2185379 on survival whereas significantly worse prognosis was observed in postmenopausal patients (HR = 2.49; 95%CI 1.90-3.26; p= 4.14 × 10 - 11) with mortality linearly increasing with age (HR = 1.05 per year; 95%CI 1.04-1.07; p= 2 × 10 - 6), in patients diagnosed with non-high-grade serous OC (HR = 0.44; 95%CI 0.32-0.60; p= 1.95 × 10 - 7) and in patients carrying a gBRCA1 pathogenic variant (HR = 0.65; 95%CI 0.48-0.87; p= 4.53 × 10 - 3). The multivariate analysis interrogating the effect of PRDM1 rs2185379 with other significant prognostic factors revealed marginal association of PRDM1 rs2185379 with worse survival in postmenopausal women (HR = 1.54; 95%CI 1.01-2.38; p= 0.046). CONCLUSIONS: Unlike age at diagnosis, OC histology or gBRCA1 status, rs2185379 in PRDM1 is unlikely a marker of long-term survival in patients with advance OC.

1st Faculty of Medicine Institute of Medical Biochemistry and Laboratory Diagnostics Charles University and General University Hospital Prague Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Lheureux S., Gourley C., Vergote I. and Oza A.M., Epithelial ovarian cancer, Lancet 393 (2019), 1240–1253. PubMed

Mitamura T., Zhai T., Hatanaka K.C., Hatanaka Y., Amano T., Wang L., Tanaka S. and Watari H., Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer, Pharmgenomics Pers Med 15 (2022), 977–984. PubMed PMC

Li Q., Zhang L., You W., Xu J., Dai J., Hua D., Zhang R., Yao F., Zhou S., Huang W., Dai Y., Zhang Y., Baheti T., Qian X., Pu L., Xu J., Xia Y., Zhang C., Tang J. and Wang X., PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells, Nat Commun 13 (2022), 7677. PubMed PMC

Casamassimi A., Rienzo M., Di Zazzo E., Sorrentino A., Fiore D., Proto M.C., Moncharmont B., Gazzerro P., Bifulco M. and Abbondanza C., Multifaceted Role of PRDM Proteins in Human Cancer, Int J Mol Sci 21 (2020). PubMed PMC

Zhu Z., Wang H., Wei Y., Meng F., Liu Z. and Zhang Z., Downregulation of PRDM1 promotes cellular invasion and lung cancer metastasis, Tumour Biol 39 (2017), 1010428317695929. PubMed

Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C. and Coukos G., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med 348 (2003), 203–13. PubMed

Lhotova K., Stolarova L., Zemankova P., Vocka M., Janatova M., Borecka M., Cerna M., Jelinkova S., Kral J., Volkova Z., Urbanova M., Kleiblova P., Machackova E., Foretova L., Hazova J., Vasickova P., Lhota F., Koudova M., Cerna L., Tavandzis S., Indrakova J., Hruskova L., Kosarova M., Vrtel R., Stranecky V., Kmoch S., Zikan M., Macurek L., Kleibl Z. and Soukupova J., Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer, Cancers (Basel) 12 (2020). PubMed PMC

Chan J.K., Urban R., Cheung M.K., Osann K., Shin J.Y., Husain A., Teng N.N., Kapp D.S., Berek J.S. and Leiserowitz G.S., Ovarian cancer in younger vs older women: a population-based analysis, Br J Cancer 95 (2006), 1314–20. PubMed PMC

Gockley A., Melamed A., Bregar A.J., Clemmer J.T., Birrer M., Schorge J.O., Del Carmen M.G. and Rauh-Hain J.A., Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer, Obstet Gynecol 129 (2017), 439–447. PubMed PMC

McLaughlin J.R., Rosen B., Moody J., Pal T., Fan I., Shaw P.A., Risch H.A., Sellers T.A., Sun P. and Narod S.A., Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2, J Natl Cancer Inst 105 (2013), 141–8. PubMed PMC

Heemskerk-Gerritsen B.A.M., Hollestelle A., van Asperen C.J., van den Beek I., van Driel W.J., van Engelen K., Gomez Garcia E.B., de Hullu J.A., Koudijs M.J., Mourits M.J.E., Hooning M.J. and Boere I.A., Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study, PLoS One 17 (2022), e0275015. PubMed PMC